FAM207A

Across TCGA pan-cancer cohorts, FAM207A mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated FAM207A data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher FAM207A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated FAM207A expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

CCRCC, LUAD, and HNSC are the cancer types where FAM207A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	III,IV	0.321	0.738	.003	31	view →
LUAD	DFS	Tertile	II,III,IV	0.681	0.207	.002	10	view →
HNSC	DFS	Tertile	III,IV	0.638	0.837	.025	8	view →
LSCC	DFS	Median	II,III,IV	0.844	0.562	.021	5	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

FAM207A–CCRCC (DFS)

Open the CCRCC breakdown →